Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroid Treatment for Post-COVID-19 Persistent Interstitial Lung Disease
NCT07380152Phase 1Completed
- Sponsor
- Universidade de São Paulo
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of prednisolone in interstitial lung disease (ILD) (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Rate of radiological, functional and quality of life improvement at 10 months. Started Aug 2021; status: completed.
02
Drugs
prednisolone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07380152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380152.